Illumina Returns to Profitability in 2025, Reports $850M Net Income, Completes SomaLogic Acquisition, and Continues Share Repurchase Program

summarizeSummary

Illumina reported a return to profitability in 2025 with $850 million in net income, driven by the GRAIL spin-off and a significant gain from the reversal of an EU fine, alongside substantial share repurchases and a strategic acquisition.

check_boxKey Events

• Return to Profitability

  The company reported a net income of $850 million for the fiscal year ended December 28, 2025, a significant improvement from net losses of $1,223 million in 2024 and $1,161 million in 2023.

• GRAIL Spin-Off Financial Impact

  The completed spin-off of GRAIL in June 2024 contributed to the financial results, including a $489 million gain from the reversal of a European Commission fine accrual.

• Significant Share Repurchases

  Illumina repurchased $748 million of its common stock in 2025 under a $1.5 billion program, with $643 million remaining authorized for future repurchases.

• SomaLogic Acquisition Completed

  The acquisition of SomaLogic's proteomics business was completed on January 30, 2026, for an upfront cash payment of $350 million, expanding Illumina's multiomics strategy.

auto_awesomeAnalysis

Illumina's 2025 Annual Report on Form 10-K reveals a significant financial turnaround, moving from substantial losses in prior years to a net income of $850 million. This positive shift is bolstered by the finalization of the GRAIL spin-off, which included a notable $489 million gain from the reversal of a European Commission fine. The company also demonstrated a strong commitment to shareholder returns through $748 million in share repurchases during 2025, with a substantial amount remaining in the authorization. Strategically, the completed acquisition of SomaLogic for $350 million expands Illumina's presence in the proteomics market. While challenges in the Greater China region persist due to regulatory listings, the partial lifting of export restrictions for sequencing instruments offers a positive outlook for future business in the area. Investors should view the return to profitability and strategic moves as strong indicators of improved operational health and future growth potential, despite ongoing litigation and market headwinds.